CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 157 enrolled / 157 target
Drug / intervention
Vasopressin (USP) Injectable Solution [Vasostrict] +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03204786
NCT03204786Phase 2CompletedHigh Momentum (1.6/mo)Completion was 27mo ago
CompareCT.gov

Intranasal Vasopressin Treatment in Children With Autism

Stanford University·interventional·Posted Jul 2, 2017·Updated Jun 4, 2026

In Brief

A Phase 2 clinical trial evaluating Vasopressin (USP) Injectable Solution [Vasostrict] and Placebo for Autism and 2 related conditions. Completed, enrolled 157 participants across 1 site.

Signals

Enrolling ahead of pace

Detailed Summary

The purpose of this clinical trial is to investigate the effectiveness of vasopressin nasal spray for treating symptoms associated with autism. Vasopressin is a hormone that is produced naturally within the body and has been implicated in regulating social behaviors. It has been proposed that administration of the hormone may also help improve social functioning in individuals with autism.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAutism, Autism Spectrum Disorder, ASD
CountriesUnited States
CollaboratorsEunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)

Timeline

Phase 2CompletedFinished
201820192020202120222023202420252026
First PostedJul 2, 2017
Enrollment StartFeb 20, 2018
Primary CompletionMar 18, 2024
TodayJul 2, 2026
Enrollment to primary: 6.1 yearsPosted 9 years ago

Arms & Interventions

Vasopressin-Vasopressinexperimental

8 weeks of vasopressin nasal spray (16 international units twice daily)

Drug: Vasopressin (USP) Injectable Solution [Vasostrict]
Placebo-Vasopressinexperimental

4 weeks of placebo nasal spray followed by 4 weeks of vasopressin nasal spray (16 international units twice daily)

Drug: Vasopressin (USP) Injectable Solution [Vasostrict]Drug: Placebo
Placebo-Placeboplacebo_comparator

8 weeks of placebo nasal spray; followed by a 4 week open-label extension of vasopressin nasal spray (16 international units twice daily)

Drug: Vasopressin (USP) Injectable Solution [Vasostrict]Drug: Placebo

Interventions

Vasopressin (USP) Injectable Solution [Vasostrict]drug

Nasal Spray

Placebodrug

Placebo Nasal Spray